Recent studies have demonstrated that the combination of these two approaches yields better therapeutic outcomes for solid tumors, highlighting the potential of combining anti-VEGF drugs with immune checkpoint inhibitors for NSCLC therapy. The gene discussed is VEGFA; the disease is non-small cell lung carcinoma.